Home
About
- Our team
- Info
- David Wallace Bio
  David Wallace
  
  Founder & CEO of MPN Cancer Connection and PV Reporter | Patient Advocate
  When David was diagnosed with PV in 2009, at the age of 47, he soon learned there was limited and often conflicting information available on Myeloproliferative Neoplasms (MPNs). He also realized early on in his diagnosis, the importance of advocating for himself to best manage his polycythemia vera (PV). David was grateful for the early support and guidance of fellow MPN patients on his journey and wanted a way to give back to the MPN community. With a professional background in business administration and sociology, David has a passion for finding solutions and helping others. In 2013, David used his skill set to create PV Reporter, a comprehensive patient-focused website for MPNs. David refers to his site as a hub for patients to begin to research their cancer. Whether a patient, caregiver or healthcare provider, PV Reporter offers visitors a wealth of educational resources, patient stories, articles, and the latest news on the treatment for MPNs, helping MPN patients and their caregivers stay informed, connected and empowered. In 2015, along with the help of others, David founded a non-profit MPN Cancer Connection (MPN-CC), a patient-led 501©3 formed to create awareness that MPN patients are “cancer patients” and should have complete access to local and national programs and benefits. David’s philosophy is to educate patients to become their own advocates so that they can make informed decisions on their treatment. David’s dedication to the MPN community is further evidenced through his work and awards:
  - Selected to endorse 2018 NCCN guidelines for MPN patients by MPN Cancer Connection
  - Selected to represent the United States as a patient advocate by MPNs Advocate Network International Conference 2016-2019
  - Recipient of MPN Hero Award 2016
  - Published in MD Anderson Cancer Center MPN Focus Newsletter Fall 2016
  - Appearance on “The Doctors” TV show in 2015 to promote MPN awareness
  - Awarded Press Credentials for American Society of Hematology Conference 2014-2019
  - Contributor to Patient Power MPN educational videos
  David lives in Charlotte, North Carolina. When he’s not working, David enjoys spending time with family, listening to live music, attending outdoor festivals, watching the Carolina Panthers, riding his motorcycle, traveling and of course having his beloved Aussiedoodle Bailey by his side.
Resources
- Partners
- Groups
MPN-CC Vision
Donate
- Corporate Sponsors
Blog
Contact

Donate

Blog

January 2, 2017

Published by mpncancer at January 2, 2017

Categories

Dying for Answers – Radiation Link to Myeloproliferative Neoplasms

Long Term Exposure to Radiation puts you at higher risk for MPN The Savannah River Site is on a list of qualified places for Special Exposure […]

December 21, 2016

Published by mpncancer at December 21, 2016

Categories

Blog
survey

Survey Seeking Essential Thrombocythemia Patients to Share Their Experiences

A survey is being conducted to learn more about the most common symptoms experienced by ET patients, and how these symptoms affect the lives of patients. […]

October 18, 2016

Published by mpncancer at October 18, 2016

Categories

Is a Cure for Blood Cancer Around the Corner?

New Leukemia Research in Phase I/IIa Clinical Trial Biosight, an Israeli pharmaceutical development company that is working on a cure for leukemia, this week closed an […]

September 21, 2016

Published by mpncancer at September 21, 2016

Categories

Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

[contentcards url=”http://www.oncologynurseadvisor.com/leukemia/factors-associated-with-hearing-loss-in-pv-pinpointed/article/523647/” target=”_blank”] “Researchers found that the mean hemoglobin and hematocrit levels of the polycythemia vera group were 16.7 g/dL and 50.4%, respectively, vs 13.4 g/dL […]

September 20, 2016

Published by mpncancer at September 20, 2016

Categories

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Key points The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in […]

August 30, 2016